Litcius/Paper detail

518MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

Satoru Kitazono, Luis Paz‐Ares, M-J. Ahn, Aaron Lisberg, Byoung Chul Cho, George R. Blumenschein, Elaine Shum, E. Pons-Tostivint, Yasushi Goto, Kiyotaka Yoh, Rebecca S. Heist, P. Baas, David Planchard, M. Pérol, Enriqueta Felip, Wu‐Chou Su, H. Zebger-Gong, Lei Lan, C. Liu, Jacob Sands

2023Annals of Oncology10 citationsDOIOpen Access PDF

Topics & Concepts

MedicineOncologynon-small cell lung cancer (NSCLC)Lung cancerCancer researchInternal medicinePathologyA549 cellLung Cancer Treatments and MutationsLung Cancer Research StudiesCancer Immunotherapy and Biomarkers
518MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs) | Litcius